Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sinovac rabies vaccine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sinovac rabies vaccine - Batch 1 | EXPERIMENTAL | Subjects will be randomly assigned to receive 5 doses of Sinovac rabies vaccine (Batch 1) on Day 0,3,7,14,28 |
| Sinovac rabies vaccine - Batch 2 | EXPERIMENTAL | Subjects will be randomly assigned to receive 5 doses of Sinovac rabies vaccine (Batch 2) on Day 0,3,7,14,28 |
| Sinovac rabies vaccine - Batch 3 | EXPERIMENTAL | Subjects will be randomly assigned to receive 5 doses of Sinovac rabies vaccine (Batch 3) on Day 0,3,7,14,28 |
| Sinovac rabies vaccine - 5 doses | EXPERIMENTAL | Subjects will be randomly assigned to receive 5 doses of Sinovac rabies vaccine on Day 0,3,7,14,28 |
| Sinovac rabies vaccine - 4-1 doses | EXPERIMENTAL | Subjects will be randomly assigned to receive 4 doses of Sinovac rabies vaccine on Day 0,3,7,14 |
| Sinovac rabies vaccine - 4-2 doses | EXPERIMENTAL | Subjects will be randomly assigned to receive 4 doses of Sinovac rabies vaccine on Day 0,3,7,28 |
| Marketed rabies vaccine - 5 doses | ACTIVE_COMPARATOR | Subjects will be randomly assigned to receive 5 doses of a marketed rabies vaccine in China on Day 0,3,7,14,28 |
| Name | Type | Description |
|---|---|---|
| Sinovac rabies vaccine | BIOLOGICAL | Three batchs of Rabies Vaccine (Serum-free Vero Cell), Freeze-dried using five doses of PEP schedules |
| Marketed rabies vaccine | BIOLOGICAL | A markted Rabies Vaccine using 5 doses of PEP schedules |
Inclusion Criteria: 1. Participants are able to understand and voluntarily sign the Informed Consent Form; 2. Able to provide legal identity documents; 3. Age 18 to 45 years; 4. Stable health status (defined as stable underlying disease status within 3 months prior to enrollment, i.e., no change in...
The Sinovac rabies vaccine is an investigational vaccine developed by Sinovac Biotech, Ltd for the prevention of rabies. It is a freeze-dried rabies vaccine produced using Vero cell technology for human use. It is being studied in healthy volunteers in China as a preventive measure against rabies infection.
The Sinovac rabies vaccine is intended for the prevention of rabies in humans. Clinical trials have enrolled healthy volunteers in China to assess its immunogenicity and safety. Rabies is a viral infectious disease, and this vaccine is being developed as a preventive immunization against it.
The Sinovac rabies vaccine is made by Sinovac Biotech, Ltd, which trades under the ticker SVA. The company is developing this freeze-dried Vero cell rabies vaccine for human use and is conducting Phase 3 clinical trials in China.
The Sinovac rabies vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved. Two Phase 3 trials have been conducted, one of which is completed and one of which is not yet recruiting, with a combined enrollment of 2,952 participants.
The Sinovac rabies vaccine has been studied in two Phase 3 trials. NCT07357545 is a completed immunogenicity and safety assessment trial with 2,040 participants. NCT07416110 is a Phase IIIb lot-to-lot consistency trial with 912 participants that is not yet recruiting. Both trials enrolled healthy volunteers in China.